Cipher Pharmaceuticals Inc. (CPHRF)

Market Cap	225.17M
Revenue (ttm)	26.46M
Net Income (ttm)	15.86M
Shares Out	n/a
EPS (ttm)	0.63
PE Ratio	14.20
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	5,600
Average Volume	15,641
Open	8.92
Previous Close	8.98
Day's Range	8.78 - 9.04
52-Week Range	4.96 - 14.60
Beta	1.18
RSI	33.65
Earnings Date	Mar 14, 2025

About Cipher Pharmaceuticals

Cipher Pharmaceuticals Inc. operates as a specialty pharmaceutical company in Canada. It offers Epuris (isotretinoin), an oral retinoid indicated for the treatment of severe nodular and/or inflammatory acne, acne conglobate, and recalcitrant acne; Actikerall, a topical solution indicated for the treatment of slightly palpable and/or moderately thick hyperkeratotic actinic keratosis (Grade I/II) of the face, forehead, and balding scalp; Ozanex for the topical treatment of impetigo; Vaniqa, a topical cream for the slowing of the growth of unwante...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 2000
• Employees: 5
• Stock Exchange: OTCMKTS
• Ticker Symbol: CPHRF

Financial Performance

In 2023, Cipher Pharmaceuticals's revenue was $21.16 million, an increase of 2.36% compared to the previous year's $20.68 million. Earnings were $20.38 million, a decrease of -23.48%.